Lucentis ranibizumab regulatory update

The U.K.'s NICE and the Scottish Medicines Consortium recommended against the use of Lucentis ranibizumab from Novartis to treat diabetic macular edema (DME). NICE issued a final appraisal

Read the full 285 word article

How to gain access

Continue reading with a
two-week free trial.